DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.
Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls and CFO Scott Kellen will participate in the Craig-Hallum Alpha Select Conference on November 17, 2020. The conference will be held virtually due to social distancing measures amid the Covid-19 pandemic. Interested institutional investors should coordinate with their Craig-Hallum representative to arrange meetings. DiaMedica is focused on developing innovative treatments for chronic kidney diseases and neurological disorders.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has provided a business update and financial results for Q3 2020. Enrollment continues in the Phase II REDUX trial for DM199, targeting chronic kidney disease (CKD), but faces challenges due to COVID-19. 49 subjects are enrolled, with expectations for rapid enrollment in Cohort III. The FDA accepted a Type B meeting request regarding DM199 for acute ischemic stroke. A $23 million public offering was completed, bolstering cash reserves to $30.6 million. R&D expenses increased to $2.2 million, while total other income decreased to $128,000.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2020 financial results after market close on November 4, 2020. A conference call to discuss these results will be held on November 5, 2020, at 7:00 AM CT. Investors can join the call via dial-in or webcast, with replay options available until November 12, 2020. DiaMedica is focused on developing treatments for chronic kidney diseases and neurological disorders.